Welcome to Mx’s (to be pronounced as emukk’s) Homepage
Current main issues on Mx homepage are as follows. Basically, Mx is a research and development type business entity.
- General biological phenomena related to Glycans and Lectins and those application to real life
- Realization of sustainable and regenerative agriculture and food safety
- Evanescent-field fluorescence excitation Glycan Profiler (GlycoStation®)
- Biosensors for detecting microbes (Optic Biome Sensor OBS)
- Easy to use Statistical Analysis & AI Software (GlycoStation®SA/DL Easy)
- R&D consumables (Culture media for MSC, Special Culture media, New Lectins, etc.)
Using lectin microarrays, glycan profiles of objects can be easily obtained. When analyzing differences in glycan profiling between objects or identifying objects based on those differences, the easiest method would be to combine it with AI. In AI architectures such as Deep Learning and Transformer used in for instance ChatGPT, the basis for the recognition is hided in “hyperparameters,” as black boxes, but their effectiveness is guaranteed. We have already developed a simple AI software product (SA/DL Easy) that analyzes lectin microarray data by applying Deep Learning more than 8 years ago.
Technical information materials focusing on biosimilar evaluation
We have added technical explanation materials on biosimilar evaluation using a custom lectin microarray (IgG1-mAb-LecChip) optimized for therapeutic antibody drug evaluation (which was jointly developed with the FDA) to our technical explanation material for GlycoStation, a platform technology for glycan profiling using lectin microarrays (LecChip). (December 1, 2025)
Glycosylation plays an important role in determining the quality and efficacy of therapeutic antibody drugs. FDA has developed a custom lectin array (IgG1-mAb-LecChip) using nine carefully selected lectins. The lectins used are designed to selectively bind to common N-glycan epitopes found on therapeutic antibody drugs. This IgG1-mAb-LecChip can directly analyze glycoprotein samples without cleaving glycans, providing a high-throughput platform for rapid and simple comparative glycan profiling. FDA emphasizes that this lectin array is highly practical for assessing differences in glycan modification between different manufacturing batches or between biosimilars and innovator drugs.
GlycoSuperLite 2200 (GSL2200)
